Sobi Pays $100m Upfront For Selecta Gout Drug
Set To Challenge Horizon’s Krystexxa
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
